European Crohn’s and Colitis Organisation

Letter from The Editor

Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines

Quiescent disease, characteristics and biomarker correlations

ILC1 distribution predicts response to ustekinumab

Central role of IL-23 in molecular resistance to anti-TNF therapy

Genetic predisposition for gut barrier dysfunction

Targeting early disease: lessons from rheumatoid arthritis

Integration of “omics” and potential for clinical practice

Combining new drugs with different mechanisms

Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response

Apremilast in active UC shows promising results

Early and significant effects with upadacitinib induction treatment

Vedolizumab induces endoscopic remission and healing in refractory CD

SHP647 is efficacious and well-tolerated in CD

Higher rates of remission and healing with vedolizumab vs. TNF antagonist

Comparative effectiveness of vedolizumab and ustekinumab in CD

Vedolizumab in anti-TNF-naïve IBD patients and safety profile

Long-term safety profile of adalimumab

Overall manageable safety profile of tofacitinib in long-term use

Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD

Cancer risk in IBD associated with age and recent immunomodulator use

Shallow whole-genome sequencing predicts future cancer risk of LGD in UC

Malignancies occur infrequently with tofacitinib

SLC12A2 potential marker of dysplasia associated to inflammation in UC

Significantly increased risk of CRC and/or HGD after appendectomy in UC

Enhanced post-operative recovery pathways for IBD patients

Higher colectomy rate with infliximab vs. conventional therapies in more severe UC

Significant reduction of emergency stoma surgeries for CD